2.31

3.59% 0.08

After Hours: 2.31

Cytomed Therapeutics Ltd (GDTC)

Overview News Price History Discussions Forecast

Cytomed Therapeutics Ltd stock is traded at $2.31, with a volume of 3,042. It is up +3.59% in the last 24 hours and down -17.79% over the past month. CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Previous Close:

$2.23

Open:

$2.25

24h Volume:

3,042

Relative Volume:

0.25

Market Cap:

$26.16M

Revenue:

Net Income/Loss:

$-3.15M

P/E Ratio:

-11.16

EPS:

-0.2069

Net Cash Flow:

$-2.23M

1W Performance:

+4.52%

1M Performance:

-17.79%

6M Performance:

+11.75%

1Y Performance:

-36.71%

1-Day Range:

$2.07

$2.35

1-Week Range:

$1.95

$2.35

52-Week Range:

$1.20

$5.50

Cytomed Therapeutics Ltd Stock (GDTC) Company Profile

Name

Cytomed Therapeutics Ltd

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GDTC's Discussions on Twitter

Compare GDTC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GDTC Cytomed Therapeutics Ltd	2.31	26.16M	0	-3.15M	-2.23M	-0.2069
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cytomed Therapeutics Ltd Stock (GDTC) Latest News

Nov 20, 2024

CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com

Nov 20, 2024

CytoMed Therapeutics Limited Announces First Patient Dosed in Its First-In-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Marketscreener.com

Nov 20, 2024

Oct 23, 2024

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St

Oct 23, 2024

Oct 17, 2024

Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch

Oct 17, 2024

Oct 16, 2024

Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks

Oct 16, 2024

Oct 08, 2024

CytoMed begins clinical trial for innovative cancer therapy - Investing.com

Oct 08, 2024

Oct 07, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com

Oct 07, 2024

Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks

Oct 07, 2024

CytoMed Launches Innovative CAR-T Cell Trial - TipRanks

Oct 07, 2024

CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa

Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire

Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan

Oct 07, 2024

Oct 04, 2024

CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance

Oct 04, 2024

Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times

Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire

Oct 03, 2024

Sep 30, 2024

GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 30, 2024

CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com

Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire

Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance

Sep 30, 2024

Sep 25, 2024

Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire

Sep 25, 2024

Aug 25, 2024

CytoMed Therapeutics Limited acquired the licence and certain assets of Cellsafe International Sdn Bhd from Cellsafe Biotech Group for MYR 2.3 million. - Marketscreener.com

Aug 25, 2024

Aug 20, 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire

Aug 20, 2024

Jul 25, 2024

CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World

Jul 25, 2024

Jul 17, 2024